Form 4 for YCBD cbdMD, Inc.
Accepted 2023-02-22 00:00:00 ET · period of report 2023-02-17 · accession 0001437749-23-004159 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-22 | 2023-02-17 | YCBD | Stephen Scott G. | Dir | A - Grant | $0.00 | +5,000 | 56.1K | +10% | $0 |
| D | 2023-02-22 | 2023-02-17 | YCBD | Stephen Scott G. | Dir | A - Grant | — | +30.0K | 30.0K | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-17 | A | A | 5,000 | $0.00 | 56,052 | D | — | — | (F1) The restricted shares of common stock were issued under the 2021 Equity Compensation Plan as compensation to the Reporting Person for his services on the Issuer's Board of Directors for the Board term beginning February 16, 2023. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of three non-employee directors. The restricted shares of common stock vest quarterly in equal increments on June 30, 2023, September 30, 2023, December 31, 2023 and March 31, 2024, subject to continued service as a director of the Issuer on each applicable vesting date. |
| 2 | Derivative | Stock Options (Right to Buy) | 2023-02-17 | A | A | 30,000 | — | 30,000 | D | $0.28 · 2023-02-17 to 2028-02-17 | 30,000 Common Stock | (F2) The stock options were granted under the 2021 Equity Compensation Plan as compensation to the Reporting Person for his services on the Issuer's Board of Directors for the Board term beginning February 16, 2023. The grant was exempt from Section 16(b) under the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder as it was approved in advance by the Issuer's Compensation, Corporate Governance and Nominating Committee, which is comprised of three non-employee directors. The stock options are fully vested. (F3) Not applicable. |